London, United Kingdom

Julian Blagg

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 63(Granted Patents)


Location History:

  • Sutton, GB (2014 - 2016)
  • Surrey, GB (2015 - 2018)
  • London, GB (2016 - 2024)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Julian Blagg in the Field of Cancer Research

Introduction

Julian Blagg, based in London, GB, is a prominent inventor with a remarkable portfolio of 19 patents. His work primarily focuses on the development of therapeutic agents aimed at combating proliferative diseases, such as cancer. Through his innovative research, Blagg has made significant strides in the field of cancer treatment, enhancing the possibilities of targeted therapies.

Latest Patents

Among his latest patents, Julian Blagg has developed inhibitor compounds that target the spindle checkpoint function of Monospindle 1 (Mps1)—also known as TTK—kinases. These compounds, detailed in his patented formulas, demonstrate the capability to inhibit Mps1 kinases, either directly or indirectly. The patents highlight their therapeutic potential as agents for the treatment and prevention of various proliferative diseases, particularly cancer. Additionally, the patents outline the processes for the preparation of these compounds and the development of pharmaceutical compositions containing them.

Career Highlights

Blagg has contributed to his field through employment with notable organizations such as Cancer Research Technology Limited and Children's Medical Center Corporation. His career reflects a dedication to advancing cancer treatments and enhancing patient care through innovative solutions.

Collaborations

Throughout his career, Julian has collaborated with esteemed colleagues including Swen Hoelder and Butrus Atrash. These partnerships have contributed to the development of groundbreaking advancements in therapeutic agents, further supporting research in the fight against cancer.

Conclusion

Julian Blagg stands out as a significant inventor in cancer research, with a focus on therapeutic innovations. His extensive patent portfolio and collaborations underline his commitment to improving treatment options for proliferative diseases. Through his work, Blagg continues to pave the way for advancements that could make a profound impact on the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…